`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`
`FRESENIUS KABI USA LLC
`
`Petitioner,
`
`
`
`v.
`
`
`
`CUBIST PHARMACEUTICALS, INC.
`
`Patent Owner.
`
`
`
`Case: IPR2015-01571
`Patent No. 8,058,238
`
`
`JOINT MOTION TO LIMIT PETITION UNDER 37 C.F.R. § 42.71
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`I.
`
`
`
`
`
`STATEMENT OF THE PRECISE RELIEF REQUESTED
`
`Pursuant to 37 C.F.R. § 42.25 and an email authorizing this motion in Inter
`
`Partes Review IPR2015-01571, which concerns U.S. Patent No. 8,058,238 (“the
`
`’238 Patent”)1 Petitioner Fresenius Kabi USA LLC (“Fresenius”) and Patent
`
`Owner Cubist Pharmaceuticals LLC (“Cubist”) jointly request that the Board (1)
`
`limit the petition to claims 98 and 187, and (2) remove 1-19, 21-44, 48-51, 53, 92-
`
`97, 99-107, 112-146, 151-167, 176, 177, 179, 183-186 and 188-189 of the ’238
`
`Patent from this consideration in this proceeding.
`
`II.
`
`STATEMENT OF FACTS
`
`Fresenius filed a petition for inter partes review on July 10, 2015, requesting
`
`review of claims 1-19, 21-44, 48-51, 53, 92-107, 112-146, 151-167, 176, 177, 179,
`
`and 183-189 of the ’238 Patent. This proceeding is still in its preliminary stages,
`
`and the Board has not yet decided whether to institute trial.
`
`Fresenius and Cubist are parties to a litigation concerning the ’238 patent in
`
`the United States District Court for
`
`the District of Delaware, Cubist
`
`Pharmaceuticals, Inc., v. Fresenius Kabi USA, LLC, C.A. No. 14-914-GMS
`
`
`1
`August 25, 2015 email from Maria Vignone, Paralegal Operations manager,
`
`Patent Trial and Appeal Board to Cynthia Lambert Hardman and other.
`
`1
`
`
`
`
`
`(D.Del.).2 In the Delaware Litigation, on August 10, 2015, Fresenius and Cubist
`
`filed, under seal, a Stipulation and Agreement to Narrow Issues in the Litigation
`
`and IPR Proceedings and Covenant Not to Sue (“Stipulation and Agreement”),
`
`wherein the parties agreed to narrow the issues in dispute in both the litigation and
`
`in this inter partes review by, inter alia, seeking to remove claims 1-19, 21-44, 48-
`
`51, 53, 92-97, 99-107, 112-146, 151-167, 176, 177, 179, 183-186 and 188-189 of
`
`the ’238 patent from consideration in this proceeding.3
`
`III. ARGUMENT
`
`A. Limiting the Petition in IPR2015-01571 is Appropriate
`
`The parties respectfully submit that the Board should limit the petition in
`
`IPR2015-01571 for at least the following reasons.
`
`
`2
`The district court litigation also involves U.S. Patent Nos. 6,468,967,
`
`6,852,689, and 8,129,342, and Fresenius has filed petitions for inter partes review
`
`concerning each of these patents, and additional petitions on the ’238 patent. See
`
`IPR2015-00223, IPR2015-00227, IPR2015-01566, IPR2015-01570, and IPR2015-
`
`01572.
`
`3
`
`A redacted public version of the Stipulation and Agreement was filed on
`
`August 17, 2015.
`
`
`
`2
`
`
`
`
`
`First, the parties are filing this joint motion before the Board has decided the
`
`merits of the proceeding. Indeed, the Patent Owner’s Preliminary Response is not
`
`yet due, and the Board has not yet decided whether to institute trial.
`
`Second, the parties have agreed to limit this proceeding in connection with a
`
`broader agreement
`
`to narrow
`
`the disputed
`
`issues
`
`in several co-pending
`
`proceedings, including multiple inter partes reviews and a district court litigation.
`
`Third, because the merits of the petition have not been determined, reducing
`
`the number of claims at this early juncture promotes efficient use of the resources
`
`of the Board, and saves expenses for the parties.
`
`B. A Copy of the Stipulation is Provided
`
`The Stipulation and Agreement has been made in writing, and a true copy is
`
`filed herewith as business confidential information pursuant to 35 U.S.C. § 317(b)
`
`and 37 C.F.R. § 42.74, as Exhibit 1041. A Joint Request to File an Agreement as
`
`Business Confidential Information under 35 U.S.C. § 317(b) and 37 C.F.R. § 42.74
`
`is also being filed herewith. The redacted public version of the Stipulation and
`
`Agreement filed in the district court litigation is also submitted herewith as Exhibit
`
`1042.
`
`C.
`
`Summary
`
`For the foregoing reasons, Fresenius and Cubist respectfully request that the
`
`Board limit the petition to claims 98 and 187, and remove claims 1-19, 21-44, 48-
`
`
`
`3
`
`
`
`
`
`51, 53, 92-97, 99-107, 112-146, 151-167, 176, 177, 179, 183-186 and 188-189
`
`from consideration in this proceeding.
`
`
`
`Respectfully submitted,
`
`/Elizabeth J. Holland/
`Elizabeth J. Holland
`Reg. No. 47,657
`Lead Attorney for Petitioner Fresenius Kabi
`USA LLC
`
`
`
`Respectfully submitted,
`
`/Emily R. Whelan/
`Emily R. Whelan
`Reg. No. 50,391
`Lead Attorney for Patent Owner Cubist
`Pharmaceuticals LLC
`
`4
`
`
`
`Dated: September 1, 2015
`
`
`
`
`
`
`Dated: September 1, 2015
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`CERTIFICATE OF SERVICE
`
`I hereby certify that “Joint Motion to Limit Petition Under 37 C.F.R. §
`
`42.71,” “Fresenius Kabi USA LLC’s Updated Exhibit List,” and Exhibits 1041 and
`
`1042 were served via electronic mail on September 1, 2015, upon:
`
`Emily R. Whelan, Emily.Whelan@wilmerhale.com
`Andrej Barbic, Ph.D., Andrej.Barbic@wilmerhale.com
`Gerard M. Devlin, Jr., Gerard.Devlin@merck.com
`Lisa A. Jakob, Lisa.Jakob@merck.com
`
`
`
`Dated: September 1, 2015
`
`
`
`
`
`
`
`
`/Ryan C. Curiel/
`Ryan C. Curiel
`GOODWIN PROCTER LLP
`The New York Times Building
`620 Eighth Avenue
`New York, New York 10018-1405
`Tel: 212-813-8800
`Fax: 212-355-3333
`rcuriel@goodwinprocter.com
`
`
`
`5